Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates

Background: Drug persistence reflects an agent’s efficacy and safety in routine practice. This study was undertaken to compare the 2-year persistence rates of three biologic disease-modifying antirheumatic drugs (bDMARDs) used to treat rheumatoid arthritis (RA) and to describe their efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Diep, Laetitia, Barbier, Vincent, Doussière, Marie, Touboul, Estelle, Jesson, Claire, Deprez, Valentine, Sobhy-Danial, Jean-Marc, Fardellone, Patrice, Goëb, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604240/
https://www.ncbi.nlm.nih.gov/pubmed/36294300
http://dx.doi.org/10.3390/jcm11205978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604240/
https://www.ncbi.nlm.nih.gov/pubmed/36294300
http://dx.doi.org/10.3390/jcm11205978

Ejemplares similares